Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 + Nimotuzumab + Chemotherapy in Advanced Pancreatic Cancer
NCT06770452Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Mar 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HRS-4642 in pancreatic cancer (PC) (5 arms), sponsored by Zhejiang University. Primary endpoint: Objective Response Rate at 2 years. Started Mar 2025; status: recruiting.
02
Drugs
HRS-4642
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06770452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770452.